[Form 4] Senti Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Event: Senti Biosciences, Inc. (SNTI) filed a Form 4 reporting that director James J. Collins was granted 21,950 stock options on 06/25/2025.

Terms of the option: the exercise price is $2.05 per share, with 100 % of the underlying shares vesting on the earlier of (i) the first anniversary of the grant date or (ii) the company’s 2026 annual meeting, provided Mr. Collins remains in service until that date. The options expire on 06/24/2035.

Ownership impact: Following this grant, Collins directly holds 21,950 derivative securities (options) and no non-derivative transactions were reported. No shares were sold or otherwise disposed of in this filing.

Sign-off: The filing was executed by attorney-in-fact Timothy Lu and dated 06/27/2025.

Insights

Financial Analyst

TL;DR: Routine director option grant; aligns incentives but has limited immediate market impact.

The Form 4 shows a typical equity-based compensation event for Senti Biosciences. Director James J. Collins received 21,950 options at a strike price of $2.05, expiring in 2035. Vesting is service-based and front-loaded to a single cliff, which is common for board compensation. No open-market purchases or sales occurred, so the transaction does not alter the public float or signal insider sentiment beyond standard incentive alignment. Given the modest size and routine nature, the filing is neutral for valuation and liquidity considerations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins James J.

(Last) (First) (Middle)

C/O SENTI BIOSCIENCES, INC.

2 CORPORATE DRIVE FIRST FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Senti Biosciences, Inc. [ SNTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.05	06/25/2025		A		21,950		(1)	06/24/2035	Common Stock	21,950	$0	21,950	D

Explanation of Responses:

1. 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Timothy Lu, attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did James J. Collins report for SNTI on Form 4?

A grant of 21,950 stock options with an exercise price of $2.05 per share.

How many Senti Biosciences options were granted to the director?

A total of 21,950 options were granted.

What is the exercise price of the newly granted SNTI options?

The exercise (strike) price is $2.05 per share.

When do the options granted to James J. Collins vest?

They vest 100 % on the earlier of the first anniversary of 06/25/2025 or the 2026 Annual Meeting.

What is the expiration date of these Senti Biosciences options?

The options will expire on 06/24/2035.

Did the director sell any SNTI shares in this filing?

No. The filing shows no disposals or sales; it only reports an option grant.